Innovate in the EP Lab | Abbott
CARDIOVASCULAR
hamburger
BACK
Bold Solutions to Challenge AFib
Innovate

Reinventing the Technology You Rely On Everyday

A solutions-based approach to innovation, Abbott’s EP portfolio is designed to improve your procedure experience. Our approach to technology helps physicians deliver better outcomes faster by focusing on three key factors:

Download Solution Portfolio

Efficiency

Get In and Out of Your Lab in Less Time


Bold technology lets you treat more patients in less time. With Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, procedure times are reduced by an average of 34 minutes versus CMCs1

HD Grid

Know You are Doing it Right the First Time

Efficiency is not just about reduction in procedure times. Bold technology should also promise less repeat procedures and reduced all-cause events. Advisor™ HD Grid Mapping Catheter has shown a 14% reduction in redo procedures compared to CMCs2 and TactiCath™ Ablation Catheter, SE results in decreased healthcare utilization by reducing all-cause annual event rates by more than 53%3

Hospital

Exposure to Radiation Matters


With no increase to procedure time, the use of our mapping system is associated with a considerable reduction in Fluoroscopy time4, radiation dosage, and laboratory staff radiation dosage.5

Hospital

REDUCED AFIB FLUORO TIME4

Accuracy

Boldness in treating AFib requires technology that never sacrifices accuracy or efficiency. Abbott’s EP portfolio delivers both.

EnSite OT map
EnSite X EP System signal image
Redefine signal quality when paired with a best-in-class high density mapping catheter that improves the signal to noise ratio with a noise floor of 0.01 mV6

Accurate contact force matters during your ablation procedures. TactiCath™ Contact Force Catheter, Sensor Enabled™ has shown 6x greater accuracy in lateral orientation for contact force ablation than the competition.6,7

Contact Force

 

Patient Outcomes

Your end goal is for your patients to be well. Abbott’s focus on creating technologies that are efficient and accurate gives you the tools you need to boldly redefine patient outcomes and change your patients’ lives. Bold solutions to challenge AFib is –

Freeing Your Patients From Atrial Arrhythmias

Advisor HD Grid and CMC data
12-month freedom from atrial arrhythmias with Advisor HD Grid Mapping Catheter, Sensor Enabled2
Agilis Nxt Steerable Sheath data
Freedom of arrhythmia at 12 months with Agilis NxT Steerable Sheath8

Driving clinical success in Paroxysmal and Persistent AFib

  • Achieving an 82.2% clinical success rate for paroxysmal AFib at one year9
  • And a 90% symptomatic success rate at 15 months - using the TactiCath Ablation Catheter, Sensor Enabled9
Chart Paroxysmal and Persistent AFib
Improved quality of life for patients at least 12 months following ablation10

 

Free Your Patients From the Use of OACS for Stroke Risk Reduction

With the Amplatzer™ Amulet™ Left Atrial Appendage Occluder (LAAO) you do both – not only delivering a 67% lower stroke rate, but also allowing 8 out of 10 patients to be discharged without OACs.12 Amplatzer Amulet LAAO is the only FDA-approved LAAO that does not require use of OACs at discharge.

Chart of ischemic stroke rate reduced
Ischemic stoke rate reduced by 67% compared to predicted risk11

ELEVATE

Clinical support that elevates your
practice to meet today's challenges

Learn More
Elevate

IMPACT

Partnerships that drive
impact for the EP community

Learn More
Impact

References

  1. Abbott. Report on file. 90299533
  2. Day, J. D., Crandall, B., Cutler, M., Osborn, J., Miller, J., Mallender, C., & Lakkireddy, D. (2020). High Power Ultra Short Duration Ablation with HD Grid Improves Freedom from Atrial Fibrillation and Redo Procedures Compared to Circular Mapping Catheter. Journal of Atrial Fibrillation, 13(2).
  3. Persist-End Final Clinical Study Report (Abbott report CL1013884).
  4. Olson N, Lo M, Zahwe F, Gururaj A, Martel JA, Bernard ML, Tao C and Venkataraman R. The effect of dynamic mapping data on procedure efficiency in radiofrequency ablation of patients with atrial fibrillation. Abstracts from the 26th Annual International Atrial Fibrillation Symposium. Journal of Cardiovascular Electrophysiology. 2021;32:1467-1515.
  5. Abbott. Data on File. Document 90114565.
  6. Bourier, F., Gianni, C., Dare, M., Deisenhofer, I., Hessling, G., Reents, T., . . . Al-Ahmad, A. (2017). Fiberoptic contact-force sensing electrophysiological catheters: how precise is the technology? Journal of Cardiovascular Electrophysiology, 28(1), 109-114.
  7. Bourier F, Deisenhofer I, Hessling G, et al. Contact-force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presentation at HRS 2016, San Francisco, CA, May 4-7, 2016. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319.
  8. Abbott. Data on File. Document 90569806.
  9. Lo MY, Sanders P, Sommer P, Kalman JM, Siddiqui UR, Sundaram S, Piorkowski C, Olson N, Madej SM and Gibson DN. Safety and Effectiveness of a Next-Generation Contact Force Catheter. JACC: Clinical Electrophysiology. 2021;0.
  10. Mansour, M. (2014) TOCCASTAR: Preliminary Results of the First Prospective Randomized Study of a Contact Force Sensing Ablation Catheter for the Treatment of Paroxysmal AF. Presented at HRS 2014. San Francisco, California.
  11. Hildick Smith D et al, Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study; European Heart Journal 2020;41(30):2894-2901.
  12. Amplatzer Amulet LAA Occluder Instructions for Use.

Important Safety Information

Advisor HD Grid Mapping Catheter

Agilis NxT Steerable Introducer

Amplatzer Amulet LAA Occluder

EnSite X EP System

TactiCath Ablation Catheter, Sensor Enabled

MAT-2208731 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

Precautions


Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.



Are you a healthcare professional?

 

Test

yesno